C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) A61K 39/395 (2006.01) C07H 21/04 (2006.01) C07K 14/47 (2006.01) C12N 15/11 (2006.01) G01N 33/53 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2389575
There is disclosed drug candidate screening assays, diagnostic assays, and therapeutic methods for tumor suppression and the treatment of cancer, including modulating induction of neuroendocrine differentiation in cancer cells, utilizing a novel IGFBP-rP1 interacting protein called P25.1 as the intervention target. The present invention further provides a P25.1 cDNA sequence, a P25.1 polypeptide and fragments thereof, an anti-P25.1 antibody, and anti-25.1 antisense oligonucleotides.
L'invention concerne des analyses par criblage de médicaments candidats, des analyses diagnostiques et des méthodes thérapeutiques destinées à la suppression de tumeurs et au traitement du cancer. Ces méthodes consistent à moduler l'induction de la différenciation neuroendocrinienne dans des cellules cancéreuses en utilisant une nouvelle protéine interagissant avec IGFBP-rP1, appelée P25.1, comme cible d'intervention. La présente invention concerne également une séquence d'ADN complémentaire de P25.1, un polypeptide de P25.1 et des fragments desdits composés, un anticorps dirigé contre P25.1 et des oligonucléotides antisens dirigés contre P25.1.
Oh Youngman
Rosenfeld Ron G.
Wilson Elizabeth
Oregon Health And Science University
Oregon Health Sciences University
Smart & Biggar
LandOfFree
Modulation of neuroendocrine differentiation by protein 25.1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of neuroendocrine differentiation by protein 25.1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of neuroendocrine differentiation by protein 25.1 will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1500298